{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:26:34Z","timestamp":1792128394972,"version":"4.4.0"},"reference-count":57,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Venetoclax, a B-cell lymphoma (BCL-2) inhibitor, in combination with hypomethylating agents has become the new standard of care in elderly and unfit patients with acute myeloid leukemia, with significantly improved overall survival and quality of life. Studies of venetoclax combined with high-dose chemotherapy are emerging with evidence of higher rates of molecular remission. Recently, a growing number of publications bring forth the use of venetoclax in patients with acute lymphoblastic leukemia (ALL). In the current review, we present the biological rationale of BCL-2 inhibition in ALL, how the interplay of BH3 proteins modulate the response and the current clinical experience with various combinations.<\/jats:p>","DOI":"10.3390\/ijms231810957","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T21:47:27Z","timestamp":1663624047000},"page":"10957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia"],"prefix":"10.3390","volume":"23","author":[{"given":"Shlomzion","family":"Aumann","sequence":"first","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-781X","authenticated-orcid":false,"given":"Adir","family":"Shaulov","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Haran","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Gross Even-Zohar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Vainstein","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-2167","authenticated-orcid":false,"given":"Boaz","family":"Nachmias","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 Protein Family: Opposing Activities That Mediate Cell Death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/17474086.2018.1456332","article-title":"Potential of BCL2 as a Target for Chronic Lymphocytic Leukemia Treatment","volume":"11","author":"Moia","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 Inhibitors for Hematologic Malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.109.060780","article-title":"The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs","volume":"77","author":"High","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and Molecular Determinants of in Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex Vivo Drug Response Profiling Detects Recurrent Sensitivity Patterns in Drug-Resistant Acute Lymphoblastic Leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1182\/blood-2014-05-574566","article-title":"ABT-199 Mediated Inhibition of BCL-2 as a Novel Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia","volume":"124","author":"Peirs","year":"2014","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and Minimal Residual Disease Are Independent Outcome Predictors in Adult Patients with Acute Lymphoblastic Leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/j.1365-2141.2008.07100.x","article-title":"Abundant Anti-Apoptotic BCL-2 Is a Molecular Target in Leukaemias with t(4;11) Translocation","volume":"141","author":"Robinson","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10509","article-title":"Inhibition of BET Recruitment to Chromatin as an Effective Treatment for MLL-Fusion Leukaemia","volume":"478","author":"Dawson","year":"2011","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/leu.2010.253","article-title":"The E2A-HLF Oncogenic Fusion Protein Acts through Lmo2 and Bcl-2 to Immortalize Hematopoietic Progenitors","volume":"25","author":"Yeung","year":"2011","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ng.3362","article-title":"Genomics and Drug Profiling of Fatal TCF3-HLF-Positive Acute Lymphoblastic Leukemia Identifies Recurrent Mutation Patterns and Therapeutic Options","volume":"47","author":"Fischer","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1158\/0008-5472.CAN-18-0236","article-title":"Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia","volume":"79","author":"Comeaux","year":"2019","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1097\/HS9.0000000000000701","article-title":"Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Hohtari","year":"2022","journal-title":"HemaSphere"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2012-06-440230","article-title":"Requirement for Antiapoptotic MCL-1 in the Survival of BCR-ABL B-Lineage Acute Lymphoblastic Leukemia","volume":"122","author":"Koss","year":"2013","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 Dependence and ABT-737 Sensitivity in Acute Lymphoblastic Leukemia","volume":"111","author":"Schlis","year":"2008","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1182\/blood-2011-12-400929","article-title":"Bcl-2, Bcl-x(L), and Bcl-w Are Not Equivalent Targets of ABT-737 and Navitoclax (ABT-263) in Lymphoid and Leukemic Cells","volume":"119","author":"Khaw","year":"2012","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41419-019-1801-0","article-title":"Prediction of Venetoclax Activity in Precursor B-ALL by Functional Assessment of Apoptosis Signaling","volume":"10","author":"Seyfried","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1593","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-XL-Dependent Resistance to the BCL-2 Inhibitor ABT-199 Can Be Overcome by Preventing PI3K\/AKT\/MTOR Activation in Lymphoid Malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood-2016-03-707414","article-title":"Venetoclax Responses of Pediatric ALL Xenografts Reveal Sensitivity of MLL-Rearranged Leukemia","volume":"128","author":"Khaw","year":"2016","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","article-title":"Maturation Stage of T-Cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199","volume":"4","author":"Chonghaile","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41375-018-0201-2","article-title":"The MCL1-Specific Inhibitor S63845 Acts Synergistically with Venetoclax\/ABT-199 to Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia Cells","volume":"33","author":"Li","year":"2019","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/bloodadvances.2021004513","article-title":"Inhibiting Casein Kinase 2 Sensitizes Acute Lymphoblastic Leukemia Cells to Venetoclax via MCL1 Degradation","volume":"5","author":"Gauert","year":"2021","journal-title":"Blood Adv."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in High-Risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv."},{"key":"ref_31","first-page":"511","article-title":"Targeting BCL-2 as a Therapeutic Strategy for Primary P210BCR-ABL1-Positive B-ALL Cells","volume":"34","author":"Massimino","year":"2020","journal-title":"Vivo Athens Greece"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.stem.2012.12.011","article-title":"A Pan-BCL2 Inhibitor Renders Bone-Marrow-Resident Human Leukemia Stem Cells Sensitive to Tyrosine Kinase Inhibition","volume":"12","author":"Goff","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"354ra114","DOI":"10.1126\/scitranslmed.aaf5309","article-title":"Targeting BCL-2 and ABL\/LYN in Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia","volume":"8","author":"Leonard","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/leu.2017.10","article-title":"Targeting BET Proteins Improves the Therapeutic Efficacy of BCL-2 Inhibition in T-Cell Acute Lymphoblastic Leukemia","volume":"31","author":"Peirs","year":"2017","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","article-title":"Activity of Vincristine, L-ASP, and Dexamethasone against Acute Lymphoblastic Leukemia Is Enhanced by the BH3-Mimetic ABT-737 in Vitro and in Vivo","volume":"110","author":"Kang","year":"2007","journal-title":"Blood"},{"key":"ref_36","first-page":"PO.18.00127","article-title":"First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia","volume":"2","author":"Numan","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1182\/blood-2019-129988","article-title":"A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed\/Refractory Acute Lymphoblastic Leukemia","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2021-153826","article-title":"A Phase II Study of Mini-Hyper-CVD Plus Venetoclax in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","volume":"138","author":"Venugopal","year":"2021","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1080\/10428194.2021.1897807","article-title":"Venetoclax with Chemotherapy in Relapse\/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia","volume":"62","author":"Arora","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00277-019-03902-9","article-title":"Relapsed\/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Was Salvaged by Venetoclax plus HAG Regimen","volume":"99","author":"Zhang","year":"2020","journal-title":"Ann. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia","volume":"20","author":"Jabbour","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Gibson, A., Trabal, A., McCall, D., Khazal, S., Toepfer, L., Bell, D.H., Roth, M., Mahadeo, K.M., Nunez, C., and Short, N.J. (2021). Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancers, 14.","DOI":"10.3390\/cancers14010150"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2021-153621","article-title":"Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152","volume":"138","author":"Palmisiano","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s40364-021-00343-3","article-title":"Daratumumab and Venetoclax in Combination with Chemotherapy Provide Sustained Molecular Remission in Relapsed\/Refractory CD19, CD20, and CD22 Negative Acute B Lymphoblastic Leukemia with KMT2A-AFF1 Transcript","volume":"9","author":"Voruz","year":"2021","journal-title":"Biomark. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00277-021-04699-2","article-title":"The First Report of Complete Remission Following Treatment with Venetoclax plus Prednisone in Elderly Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia","volume":"101","author":"Zhang","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_47","first-page":"6092646","article-title":"Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant","volume":"2018","author":"Rahmat","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.hemonc.2019.10.002","article-title":"Venetoclax and Decitabine for Treatment of Relapsed T-Cell Acute Lymphoblastic Leukemia: A Case Report and Review of Literature","volume":"14","author":"Farhadfar","year":"2021","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/ccr3.3041","article-title":"Venetoclax in Association with Decitabine as Effective Bridge to Transplant in a Case of Relapsed Early T-Cell Lymphoblastic Leukemia","volume":"8","author":"Zappone","year":"2020","journal-title":"Clin. Case Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-021-04530-y","article-title":"Venetoclax and Decitabine in Refractory TP53-Mutated Early T-Cell Precursor Acute Lymphoblastic Leukemia","volume":"101","author":"Kong","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1080\/10428194.2021.1957876","article-title":"Venetoclax Combined with Azacitidine as an Effective and Safe Salvage Regimen for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia: A Case Series","volume":"62","author":"Wan","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"E229","DOI":"10.1002\/ajh.26175","article-title":"An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed\/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","volume":"96","author":"Short","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41408-022-00621-9","article-title":"Venetoclax-Ponatinib for T315I\/Compound-Mutated Ph+ Acute Lymphoblastic Leukemia","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty Acid Metabolism Underlies Venetoclax Resistance in Acute Myeloid Leukemia Stem Cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/18\/10957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:34:18Z","timestamp":1760142858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/18\/10957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":57,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["ijms231810957"],"URL":"https:\/\/doi.org\/10.3390\/ijms231810957","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]}}}